Adial Pharmaceuticals Inc (ADIL)
NASDAQ:ADIL
Want to see ADIL full AI Analyst Report?
ADIL Stock Chart & Stats
$0.22
-$0.03(-2.80%)
At close: 4:00 PM EST
$0.22
-$0.03(-2.80%)
Day’s Range― - ―
52-Week Range$1.31 - $18.90
Previous CloseN/A
Volume36.45K
Average Volume (3M)746.19K
Market Cap
$6.39M
Enterprise Value-$2.28M
Total Cash (Recent Filing)$4.58M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 19, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.78
Shares Outstanding2,143,621
10 Day Avg. Volume779,793
30 Day Avg. Volume746,186
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.70
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap-0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.18K
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$7.00Price Target Upside3081.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial Leverage (no Debt)Total debt of $0 materially reduces refinancing and interest-rate risk for a clinical-stage biotech. This durable strength preserves financial flexibility to allocate capital toward trials and development rather than fixed interest obligations, improving resilience while external funding is arranged.
Up To $64M Financing Secured Via Azora MergerThe Azora transaction and committed up-to-$64M financing provide meaningful runway to advance AT177 through early clinical milestones. This structural capital reduces immediate funding pressure, enabling execution of development plans and increasing the probability of reaching value-creating inflection points.
Strengthened R&D Leadership And Strategic PivotBringing experienced drug-development leadership and a clear pivot to inflammatory disease enhances execution capability. Durable improvement in technical leadership raises the odds of disciplined clinical development and more effective go-to-market or partnering strategies over the medium term.
Bears Say
Pre-revenue With Sustained LossesOperating with no product revenue and persistent net losses means the company lacks internal cash generation to fund operations. This structural profitability gap forces ongoing capital raises or partnerships and keeps margins and return prospects uncertain until commercialization or licensing occurs.
Consistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow make the business reliant on external capital to sustain R&D and trials. This persistent cash burn is a structural vulnerability that can delay programs, force unfavorable financing terms, or dilute shareholders if milestones are not reached.
Governance And Dilution Risk From Merger TermsCreation of a new preferred class, broad equity inducements, and a control shift to Azora stakeholders structurally raise dilution and governance risks. These capital-structure changes can alter shareholder rights, complicate future financings, and materially affect long-term return dynamics for legacy investors.
Adial Pharmaceuticals News
ADIL FAQ
What was Adial Pharmaceuticals Inc’s price range in the past 12 months?
Adial Pharmaceuticals Inc lowest stock price was $1.31 and its highest was $18.90 in the past 12 months.
What is Adial Pharmaceuticals Inc’s market cap?
Adial Pharmaceuticals Inc’s market cap is $6.39M.
When is Adial Pharmaceuticals Inc’s upcoming earnings report date?
Adial Pharmaceuticals Inc’s upcoming earnings report date is Aug 19, 2026 which is in 65 days.
How were Adial Pharmaceuticals Inc’s earnings last quarter?
Adial Pharmaceuticals Inc released its earnings results on May 11, 2026. The company reported -$1.48 earnings per share for the quarter, beating the consensus estimate of -$2.73 by $1.25.
Is Adial Pharmaceuticals Inc overvalued?
According to Wall Street analysts Adial Pharmaceuticals Inc’s price is currently Undervalued.
Does Adial Pharmaceuticals Inc pay dividends?
Adial Pharmaceuticals Inc does not currently pay dividends.
What is Adial Pharmaceuticals Inc’s EPS estimate?
Adial Pharmaceuticals Inc’s EPS estimate is -1.07.
How many shares outstanding does Adial Pharmaceuticals Inc have?
Adial Pharmaceuticals Inc has 2,143,621 shares outstanding.
What happened to Adial Pharmaceuticals Inc’s price movement after its last earnings report?
Adial Pharmaceuticals Inc reported an EPS of -$1.48 in its last earnings report, beating expectations of -$2.73. Following the earnings report the stock price went up 0.699%.
Which hedge fund is a major shareholder of Adial Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ADIL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
ADIL Stock 12 Month Forecast
Average Price Target
$7.00
▲(3081.82% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Kiora Pharmaceuticals
―
Matinas BioPharma
―
Alzamend Neuro
―
Calidi Biotherapeutics
―
Ownership Overview
4.80% Insiders
0.29% Mutual Funds
0.09% Other Institutional Investors
94.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---